Marcio Souza

Insider Reports History

Reporting-owner location: South Plainfield, NJ
Latest reporting-owner signature: /s/ Alex Nemiroff, as Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Marcio Souza

Form 4 holding Chief Executive Officer, Director

Praxis Precision Medicines, Inc.

Security class: Common Stock
Shares / value: 77,016
Estimated value: $24,813,785
Report date: 14 May 2026
Price: $322.19
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Praxis Precision Medicines, Inc.

Security class: Common Stock
Shares / value: 2,600
Estimated value: $837,694
Report date: 14 May 2026
Price: $322.19
Ownership: Held by spouse

Form 4 holding Director

Aeglea BioTherapeutics, Inc.

Security class: Common Stock
Shares / value: 90,000
Estimated value: $63,900
Report date: 25 Aug 2022
Price: $0.7100
Ownership: Direct

Form 4 holding Chief Executive Officer, Director

Praxis Precision Medicines, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 22,110
Estimated value
Report date: 08 Jan 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Marcio Souza

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 14 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 19 May 2026, 21:42
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 08 Jan 2026
Transactions: 3
Transaction value: -$1,226,489
Accepted by SEC: 12 Jan 2026, 17:48
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 07 Jan 2026
Transactions: 1
Transaction value: -$118,515
Accepted by SEC: 09 Jan 2026, 16:46
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 30 Dec 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 31 Dec 2025, 19:17
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 14 May 2025
Transactions: 1
Transaction value: +$10,974
Accepted by SEC: 19 May 2025, 16:57
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 Feb 2025
Transactions: 1
Transaction value: -$34,245
Accepted by SEC: 14 Feb 2025, 16:29
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 10 Jan 2025
Transactions: 2
Transaction value: $0
Accepted by SEC: 14 Jan 2025, 18:50
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 07 Jan 2025
Transactions: 1
Transaction value: -$33,644
Accepted by SEC: 08 Jan 2025, 19:50
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 29 Jul 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 31 Jul 2024, 21:03
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 14 May 2024
Transactions: 1
Transaction value: +$21,248
Accepted by SEC: 20 May 2024, 08:10
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 Feb 2024
Transactions: 1
Transaction value: -$12,100
Accepted by SEC: 14 Feb 2024, 16:10
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jan 2024, 16:49
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 07 Jan 2024
Transactions: 1
Transaction value: -$10,529
Accepted by SEC: 09 Jan 2024, 21:09
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 27 Jun 2023
Transactions: 1
Transaction value: +$10,587
Accepted by SEC: 27 Jun 2023, 19:52
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 May 2023
Transactions: 1
Transaction value: +$10,331
Accepted by SEC: 18 May 2023, 21:47
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 23 Mar 2023
Transactions: 2
Transaction value: +$60,366
Accepted by SEC: 27 Mar 2023, 13:12
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jan 2023, 18:34
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 12 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 13 Jan 2023, 06:47
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 14 Nov 2022
Transactions: 1
Transaction value: +$3,830
Accepted by SEC: 21 Nov 2022, 05:07
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SYRE

Aeglea BioTherapeutics, Inc.

Report period: 25 Aug 2022
Transactions: 1
Transaction value: +$50,472
Accepted by SEC: 25 Aug 2022, 19:37
Role: Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 22 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 24 Jun 2022, 16:45
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 08 Jun 2022
Transactions: 1
Transaction value: +$49,888
Accepted by SEC: 09 Jun 2022, 19:25
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SYRE

Aeglea BioTherapeutics, Inc.

Report period: 07 Jun 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 09 Jun 2022, 21:21
Role: Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 13 May 2022
Transactions: 1
Transaction value: +$12,247
Accepted by SEC: 18 May 2022, 17:39
Role: Chief Executive Officer, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 07 Jan 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 11 Jan 2022, 15:09
Role: President and CEO, Director
Next action: Open filing details

4 PRAX

Praxis Precision Medicines, Inc.

Report period: 18 Aug 2021
Transactions: 1
Transaction value: +$150,668
Accepted by SEC: 19 Aug 2021, 18:33
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SYRE

Aeglea BioTherapeutics, Inc.

Report period: 18 Jun 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 16:07
Role: Director
Next action: Open filing details

3 SYRE

Aeglea BioTherapeutics, Inc.

Report period: 18 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 22 Jun 2021, 16:06
Role: Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .